Navigation Links
TGen becomes center of excellence for Horizon Discovery's GENESIS and X-MAN technology

PHOENIX, Ariz. Feb. 2, 2010 The Translational Genomics Research Institute (TGen) and Horizon Discovery today announced plans to develop human disease models for use in TGen's cancer research.

A research-collaboration and sub-licensing agreement will allow TGen investigators to use Horizon's GENESIS and X-MAN technologies to accelerate the search for new drug targets, biomarkers and anti-cancer agents, which could provide patients with more effective treatments.

Dr. Daniel Von Hoff, TGen's Physician-In-Chief and senior investigator will head the effort at TGen. Dr. Von Hoff is a leading advocate of developing precision cancer therapies. Dr. Von Hoff also is a leader in clinical trial design for agents that are based on an understanding of the cancer genes in patients' tumors.

"TGen is eager to partner with Horizon in the use of these new technologies, which should enhance our research efforts to provide patients with significantly better outcomes,'' Dr. Von Hoff said.

Horizon's core gene-targeting technology and human isogenic cell-lines are expected to enable TGen to create a key center of excellence in translational medicine for generating and applying predictive human disease models in drug discovery.

"Our over-arching mission is to speed up the research, development and prescription of more rational therapies that target the root causes of cancer development in each patient's tumor," said Dr. Chris Torrance, CEO of Horizon, based in Cambridge, U.K. "TGen investigators are visionaries in this respect and we are honored to enable them with Horizon's GENESIS technology to generate a novel pipeline of X-MAN cancer models to support cutting-edge translational oncology research."

Under terms of the collaboration, TGen will use Horizon proprietary technology and know-how to develop a panel of novel cancer cell-lines, which will be licensed back to Horizon for future licensing to the broader academic, biotech and pharma research communities. The parties also have agreed to share, publish and commercialize data from the research program, subject to future commercial terms.

This type of open-source relationship will be replicated in the future by Horizon at selected centers of excellence for translational research with the aim of deciphering the genetic links to cancer and other debilitating diseases.


Contact: Steve Yozwiak
The Translational Genomics Research Institute

Related biology news :

1. UNH becomes first university in nation to use landfill gas as primary energy source
2. Scientists find how amber becomes death trap for watery creatures
3. Complete Genomics launches, becomes worlds first large-scale human genome sequencing company
4. Time running out on coral reefs as climate change becomes increasing threat
5. Italys geologic history becomes a personal tale in Walter Alvarezs new book
6. Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find
7. Georgia Tech/Emory Center to study origin of life
8. Woods Hole Research Center to lead undergraduate initiative in the Siberian Arctic
9. $10 million gift to support cutting-edge epigenome center at USC
10. 3 Columbia University Medical Center faculty elected to Institute of Medicine
11. NHGRI funds new Centers for Excellence in Ethical, Legal and Social Implications Research
Post Your Comments:
(Date:11/10/2015)... NEW YORK , Nov. 10, 2015 /PRNewswire/ ... refers to behavioral biometrics that helps to identify ... prevent fraud. Signature is considered as the secure ... for the identification of a particular individual because ... offers more accurate results especially when dynamic signature ...
(Date:11/9/2015)... Calif. , Nov. 9, 2015  Synaptics Inc. ... interface solutions, today announced broader entry into the automotive ... solutions that match the pace of consumer electronics human ... biometric sensors are ideal for the automotive industry and ... Europe , ...
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has been ... provide preclinical development services to the National Cancer Institute ... will provide scientific expertise, modern testing and support facilities, ... preclinical pharmacology and toxicology studies to evaluate potential cancer ... The PREVENT Cancer Drug Development Program is an ...
Breaking Biology News(10 mins):
(Date:11/27/2015)... ... November 27, 2015 , ... Pittcon ... over 2,000 technical presentations offered in symposia, oral sessions, workshops, awards, and posters. ... a wide range of applications such as, but not limited to, biotechnology, biomedical, ...
(Date:11/25/2015)... -- PharmAthene, Inc. (NYSE MKT: PIP) announced  today that its ... (Rights Plan) in an effort to preserve the value ... 382 of the Internal Revenue Code (Code). ... its NOLs could be substantially limited if the Company ... of the Code. In general, an ownership change occurs ...
(Date:11/25/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: AEZ) ... remain fundamentally strong and highlights the following developments: ... DSMB recommendation to continue the ZoptEC Phase 3 ... final interim efficacy and safety data , ... with heavily pretreated castration- and Taxane-resistant prostate cancer ...
(Date:11/24/2015)... , Nov. 24, 2015  Asia-Pacific (APAC) holds ... organisation (CRO) market. The trend of outsourcing to ... margins but higher volume share for the region ... scale, however, margins in the CRO industry will ... Market ( ), finds that the ...
Breaking Biology Technology: